secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000950170-25-061851
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance
-------------------------------------------------------------------------

- Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.
- Net loss narrowed to $29.8M from $47.5M; adjusted EBITDA loss $12.7M from $28.2M.
- Raises FY 2025 MRD revenue guidance to $180-190M (from $175-185M); lowers cash burn target to $50-60M.
- Expanded Medicare coverage for clonoSEQ in mantle cell lymphoma recurrence monitoring.
- Cash, equivalents, and marketable securities $232.8M at March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017025061851/0000950170-25-061851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017025061851/adpt-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-061851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer